Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 384

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

Open access
Schrock, Alexa B., Frampton, Garrett M., Suh, James, Chalmers, Zachary R., Rosenzweig, Mark, Erlich, Rachel L., Halmos, Balazs, Goldman, Jonathan, Forde, Patrick, Leuenberger, Kurt, Peled, Nir, Kalemkerian, Gregory P., Ross, Jeffrey S., Stephens, Philip J., Miller, Vincent A., Ali, Siraj M., Ou, Sai-Hong Ignatius·2016·Journal of Thoracic Oncology

Abstract

BACKGROUND: The hepatocyte growth factor receptor gene (MET) exon 14 skipping (METex14) has recently been described a potential driver alteration in lung cancer targetable by mesenchymal-to-epithelial transition factor (MET) tyrosine kinase inhibitors (TKIs). METHODS: Well-validated hybrid capture-based comprehensive genomic profiling was performed at the request of individual treating physicians. RESULTS: Of 11,205 lung cancers profiled by comprehensive genomic profiling, 298 (2.7%) carcinomas harbored alterations predicted to cause METex14, including adenosquamous (8.2%), sarcomatoid (7.7%), histologic subtype not otherwise specified (3.0%), adenocarcinoma (2.9%), squamous cell (2.1%), large cell (0.8%), and SCLC (0.2%). Acinar features were present in 24% of the METex14 samples. Six cases (2%) harbored MET Y1003X mutations affecting binding of the MET-negative regulator, E3 ubiquitin protein ligase. The median age of all patients with METex14 was 73 years (range 43-95) and 60% were female. Concurrent, murine double minute gene (MDM2) amplification, cyclin-dependent kinase 4 gene (CDK4) amplification, and EGFR amplification were observed in 35%, 21%, and 6.4% of patients with METex14, respectively. KRAS mutation was observed in 3% of cases. Concurrent MET amplification (METamp) (median copy number 10) was identified in 15% of METex14 samples. Significant differences in tumor mutational burden and type of the METex14 alterations were observed between the METamp and non-METamp samples. Response to MET TKI was observed in both in patients with METamp and in patients without METamp METex14. CONCLUSION: Diverse targetable METex14 alterations were identified in patients with NSCLC across age groups, including elderly patients, and in all major NSCLC histologic subtypes with an overall frequency of 2.7%. These findings support the use of hybrid capture-based molecular profiling across NSCLC subtypes to identify patients who will potentially benefit from MET TKIs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2016.06.004

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 384

Metadata

Authors
Schrock, A. B., Frampton, G. M., Suh, J., Chalmers, Z. R., Rosenzweig, M., Erlich, R. L., Halmos, B., Goldman, J., Forde, P., Leuenberger, K., Peled, N., Kalemkerian, G. P., Ross, J. S., Stephens, P. J., Miller, V. A., Ali, S. M., & Ou, S.-H. I.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2016-09
Volume
11
Issue
9
Pages
1493-1502
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2466657922
Cited by
384
References
29
FWCI
25.69
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. https://app.cochat.ai/papers/10.1016/j.jtho.2016.06.004
The paper
Schrock, A. B., Frampton, G. M., Suh, J., Chalmers, Z. R., Rosenzweig, M., Erlich, R. L., Halmos, B., Goldman, J., Forde, P., Leuenberger, K., Peled, N., Kalemkerian, G. P., Ross, J. S., Stephens, P. J., Miller, V. A., Ali, S. M., & Ou, S.-H. I. (2016). Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2016.06.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.